Hyperion Biosystems
Hyperion Biosystems, an MIT spin-out tough tech company, is developing revolutionary diagnostics at the interface of chemistry, biology, and algorithms to address medicine’s most expensive blind spot – sepsis. Our flagship molecular platform (Helios™) is able to simultaneously detect tens to hundreds of target species, direct-from-blood, with excellent sensitivity (single-copy) and specificity (VAFs in excess of 0.0001%). These capabilities are tailer-made for rapid, pre-culture, pathogen identification (ID) and antimicrobial resistance (AMR) marker detection in patients with suspected bloodstream infection (BSI) or sepsis.
Industries
Nr. of Employees
small (1-50)
Hyperion Biosystems
Hyperion Biosystems is currently seeking investment
Hyperion Biosystems is seeking a series-a investment in the range of 5m-20m
Products
Low cost, fully connected reader system for rapid diagnostics
A hardware-software integrated reader platform that boosts diagnostic assay sensitivity and specificity, compatible with rapid diagnostic assays.
Helios
Platform molecular technology that leverages a combination of padlock probe chemistry, isothermal amplification, and optical detection to enable pre-culture detection and identification of >95% of sepsis-causing pathogens (bacterial and fungi) at single-copy level with a 3 hour turnaround time.
Authentication and anti-counterfeiting solution for solid oral dosage products
Technology for on-dose authentication to prevent counterfeiting of pharmaceutical and nutraceutical tablets and capsules.
Low cost, fully connected reader system for rapid diagnostics
A hardware-software integrated reader platform that boosts diagnostic assay sensitivity and specificity, compatible with rapid diagnostic assays.
Helios
Platform molecular technology that leverages a combination of padlock probe chemistry, isothermal amplification, and optical detection to enable pre-culture detection and identification of >95% of sepsis-causing pathogens (bacterial and fungi) at single-copy level with a 3 hour turnaround time.
Authentication and anti-counterfeiting solution for solid oral dosage products
Technology for on-dose authentication to prevent counterfeiting of pharmaceutical and nutraceutical tablets and capsules.
Expertise Areas
- Diagnostic assay research and development
- Digital health and connected diagnostics
- Computer vision in diagnostics
- Physics-based algorithm design
Key Technologies
- Computer vision algorithms
- Physics-based diagnostic algorithms
- AI-enhanced diagnostic software
- Isothermal amplification
Key People
Mary Rose Durante
Chief Operations Officer
Robert Deans, Ph.D.
Chief Executive Officer
Joseph Walish, Ph.D.
Chief Technology Officer
Nicole Terry
Engineer
Alex Petty
Scientist
Brian Fratto, Ph.D.
Senior Scientist
Mary Rose Durante
Chief Operations Officer
Robert Deans, Ph.D.
Chief Executive Officer
Joseph Walish, Ph.D.
Chief Technology Officer
Nicole Terry
Engineer
Alex Petty
Scientist
Brian Fratto, Ph.D.
Senior Scientist
Investors
Series C - Hyperion Biosystems
National Institute of Biomedical Imaging and Bioengineering
Series B - Hyperion Biosystems
Convertible Note - Hyperion Biosystems
Moore Capital, Safar Partners
The Engine
Series C - Hyperion Biosystems
National Institute of Biomedical Imaging and Bioengineering
Series B - Hyperion Biosystems
Convertible Note - Hyperion Biosystems
Moore Capital, Safar Partners
The Engine
News & Updates
Algorithms have powered over 10,000 diagnostic assay runs.
Describes the use of smartphone cameras for time-gated luminescence diagnostic measurements.
Entered into a licensing agreement to commercialize a jointly developed anti-counterfeiting technology for pharmaceutical and nutraceutical solid oral dosage products.
Received NIH RADx program award for connected at-home diagnostic reader with multiplex COVID-19/flu A&B rapid test.
Published a study demonstrating time-gated luminescence measurements using smartphone cameras.
Awarded NIH RADx Tech funding to advance a digitally connected at-home reader for improving sensitivity of COVID-19/flu diagnostic tests.
Algorithms have powered over 10,000 diagnostic assay runs.
Describes the use of smartphone cameras for time-gated luminescence diagnostic measurements.
Entered into a licensing agreement to commercialize a jointly developed anti-counterfeiting technology for pharmaceutical and nutraceutical solid oral dosage products.
Received NIH RADx program award for connected at-home diagnostic reader with multiplex COVID-19/flu A&B rapid test.
Published a study demonstrating time-gated luminescence measurements using smartphone cameras.
Awarded NIH RADx Tech funding to advance a digitally connected at-home reader for improving sensitivity of COVID-19/flu diagnostic tests.